References
1. Chan YY, Jayaprakasan K, Zamora J, Thornton JG, Raine-Fenning N CA.
The Prevalence of Congenital Uterine Anomalies in Unselected and
High-Risk Populations: A Systematic Review - PubMed. Hum Reprod Update.
2011. p. 17(6):761-771.
2. Grimbizis GF, Gordts S, Di Spiezio Sardo A, Brucker S, De Angelis C,
Gergolet M, et al. The ESHRE-ESGE consensus on the classification of
female genital tract congenital anomalies. Gynecol Surg. 2013
Aug;10(3):199–212.
3. Buttram VC, Gomel V, Siegler A, DeCherney A, Gibbons W, March C. The
American Fertility Society classifications of adnexal adhesions, distal
tubal occlusion, tubal occlusion secondary to tubal ligation, tubal
pregnancies, Mullerian anomalies and intrauterine adhesions. Fertil
Steril. 1988;49(6):944–55.
4. Bozdag G, Mumusoglu S, Zengin D, Karabulut E YB. The Prevalence and
Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review
and Meta-Analysis - PubMed. Hum Reprod. 2016;31(12):2841‐2855. 2016. p.
31(12):2841-2855.
5. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson
O. Risk of adverse pregnancy outcomes in women with polycystic ovary
syndrome: Population based cohort study. BMJ. 2011 Oct 22;343(7828).
6. Wang T, Fu H, Chen L, Xu Y. Pregnancy complications among women with
polycystic ovary syndrome in China: A Meta-analysis. J Cent South Univ
(Medical Sci. 2017 Nov 1;42(11):1300–10.
7. Palomba S, De Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM.
Pregnancy complications in women with polycystic ovary syndrome. Hum
Reprod Update. 2015;21(5):575–92.
8. Hu KL, Liu FT, Xu H, Li R, Qiao J. High antimüllerian hormone levels
are associated with preterm delivery in patients with polycystic ovary
syndrome. Fertil Steril. 2020 Feb 1;113(2):444-452.e1.
9. Hsu JY, James KE, Bormann CL, Donahoe PK, Pépin D, Sabatini ME.
Müllerian-inhibiting substance/anti-Müllerian hormone as a predictor of
preterm birth in polycystic ovary syndrome. J Clin Endocrinol Metab.
2018;103(11):4187–96.
10. Valdimarsdottir R, Valgeirsdottir H, Wikström AK, Kallak TK, Elenis
E, Axelsson O, et al. Pregnancy and neonatal complications in women with
polycystic ovary syndrome in relation to second-trimester anti-Müllerian
hormone levels. Reprod Biomed Online. 2019 Jul 1;39(1):141–8.
11. Taylor HS, Vanden Heuvel GB, Igarashi P. A Conserved Hox Axis in the
Mouse and Human Female Reproductive System: Late Establishment and
Persistent Adult Expression of the Hoxa Cluster Genes. Biol Reprod. 1997
Dec 1;57(6):1338–45.
12. Lewis EB. A gene complex controlling segmentation in Drosophila.
Vol. 276, Nature. Nature; 1978. p. 565–70.
13. McGinnis W, Garber RL, Wirz J, Kuroiwa A, Gehring WJ. A homologous
protein-coding sequence in drosophila homeotic genes and its
conservation in other metazoans. Cell. 1984;37(2):403–8.
14. McGinnis W, Levine MS, Hafen E, Kuroiwa A, Gehring WJ. A conserved
DNA sequence in homoeotic genes of the Drosophila Antennapedia and
bithorax complexes. Nature. 1984;308(5958):428–33.
15. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Vol.
68, Cell. Cell; 1992. p. 283–302.
16. Mullen RD, Behringer RR. Molecular genetics of Müllerian duct
formation, regression and differentiation. Sex Dev. 2014 Sep
1;8(5):281–96.
17. Krumlauf R. Hox genes in vertebrate development. Vol. 78, Cell.
Cell; 1994. p. 191–201.
18. Block K, Kardana A, Igarashi P, Taylor HS. In utero
diethylstilbestrol (DES) exposure alters Hox gene expression in the
developing mullerian system. FASEB J. 2000 Jun;14(9):1101–8.
19. Massé J, Watrin T, Laurent A, Deschamps S, Guerrier D, Pellerin I.
The developing female genital tract: From genetics to epigenetics. Vol.
53, International Journal of Developmental Biology. Int J Dev Biol;
2009. p. 411–24.
20. Benson G V., Lim H, Paria BC, Satokata I, Dey SK, Maas RL.
Mechanisms of reduced fertility in Hoxa-10 mutant mice: Uterine homeosis
and loss of maternal Hoxa-10 expression. Development.
1996;122(9):2687–96.
21. Cheng Z, Zhu Y, Su D et al. A Novel Mutation of HOXA10 in a Chinese
Woman With a Mullerian Duct Anomaly - PubMed. Hum Reprod. 2011. p.
26(11):3197-3201.
22. Filippou P HR. Is Foetal Hyperexposure to Androgens a Cause of PCOS?
- PubMed. Hum Reprod Update. . 2017. p. 23(4):421-432.
23. Piltonen TT, Giacobini P, Edvinsson Å, Hustad S, Lager S,
Morin-Papunen L, et al. Circulating antimüllerian hormone and steroid
hormone levels remain high in pregnant women with polycystic ovary
syndrome at term. Fertil Steril. 2019 Mar 1;111(3):588-596.e1.
24. Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N,
Sir-Petermann T. Placental steroidogenesis in pregnant women with
polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol.
2013;166(2):151–5.
25. Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, et al.
Novel role for anti-Müllerian hormone in the regulation of GnRH neuron
excitability and hormone secretion. Nat Commun. 2016 Jan 12;7.
26. Tadaion Far F, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A.
Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in
the newborns of mothers with polycystic ovary syndrome (PCOS) and
healthy mothers. J Ovarian Res. 2019 Nov 17;12(1).
27. Hirobe S, He WW, Lee MM, Donahoe PK. Mullerian inhibiting substance
messenger ribonucleic acid expression in granulosa and sertoli cells
coincides with their mitotic activity. Endocrinology.
1992;131(2):854–62.
28. Guibourdenche J, Lucidarme N, Chevenne D, Rigal O, Nicolas M, Luton
D, et al. Anti-Müllerian hormone levels in serum from human foetuses and
children: Pattern and clinical interest. In: Molecular and Cellular
Endocrinology. Elsevier Ireland Ltd; 2003. p. 55–63.
29. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et
al. Mullerian inhibiting substance in humans: normal levels from infancy
to adulthood. J Clin Endocrinol Metab. 1996 Feb;81(2):571–6.
30. Rajpert-De Meyts E, Jørgensen N, Græm N, Müller J, Cate RL,
Skakkebæk NE. Expression of Anti-Müllerian Hormone during Normal and
Pathological Gonadal Development: Association with Differentiation of
Sertoli and Granulosa Cells 1 . J Clin Endocrinol Metab. 1999
Oct;84(10):3836–44.
31. Kuiri-Hänninen T, Kallio S, Seuri R, Tyrväinen E, Liakka A,
Tapanainen J, et al. Postnatal developmental changes in the
pituitary-ovarian axis in preterm and term infant girls. J Clin
Endocrinol Metab. 2011 Nov;96(11):3432–9.
32. Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M, Cleemann L, et
al. Serum levels of anti-Müllerian hormone as a marker of ovarian
function in 926 healthy females from birth to adulthood and in 172
turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–10.
33. Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, et
al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and
induces polycystic ovary syndrome in adulthood. Nat Med. 2018 Jun
1;24(6):834–46.
34. Hart R, Sloboda DM, Doherty DA, Norman RJ, Atkinson HC, Newnham JP,
et al. Circulating maternal testosterone concentrations at 18 weeks of
gestation predict circulating levels of antimüllerian hormone in
adolescence: A prospective cohort study. Fertil Steril. 2010
Sep;94(4):1544–7.
35. Franco HL, Dai D, Lee KY, Rubel CA, Roop D, Boerboom D, et al. WNT4
is a key regulator of normal postnatal uterine development and
progesterone signaling during embryo implantation and decidualization in
the mouse. FASEB J. 2011 Apr;25(4):1176–87.
36. Di Spiezio Sardo A, Florio P, Nazzaro G, Spinelli M, Paladini D, Di
Carlo C, et al. Hysteroscopic outpatient metroplasty to expand
dysmorphic uteri (HOME-DU technique): A pilot study. Reprod Biomed
Online. 2015 Feb 1;30(2):166–74.
37. Alonso L, Haimovich S, Di Spiezio Sardo A, Carugno J. Dysmorphic
Uterus: Do We Need a T-Y-I Subclassification? Vol. 27, Journal of
Minimally Invasive Gynecology. Elsevier B.V.; 2020. p. 4–6.